RT Journal Article
T1 Safety and Tolerability of More than Six Days of Tedizolid Treatment.
A1 Mensa Vendrell, Mireia
A1 Tasias Pitarch, Maria
A1 Salavert Lletí, Miguel
A1 Calabuig Muñoz, Eva
A1 Morata Ruiz, Laura
A1 Castells Lao, Genís
A1 López Suñé, Ester
A1 Mensa Pueyo, Jose
A1 Oltra Sempere, Maria Rosa
A1 Pedro-Botet Montoya, Maria-Luisa
A1 Isernia, Valentina
A1 Reynaga Sosa, Esteban Alberto
A1 Moreno Nuñez, Leonor
A1 Pasquau Liaño, Juan
A1 Sequera Arquelladas, Sergio
A1 Yuste Ara, José Ramón
A1 Soriano Viladomiu, Alex
K1 adverse events
K1 safety
K1 tedizolid
K1 tolerability
AB Tedizolid has demonstrated its efficacy and safety in clinical trials; however, data concerning its tolerability in long-term treatments are scarce. The aim of the study was to assess the indications and to describe the long-term safety profile of tedizolid. A multicentric retrospective study of patients who received tedizolid for more than 6 days was conducted. Adverse events (AEs) were identified from patients' medical records and laboratory data. The World Health Organization causality categories were used to discern AEs that were probably associated with tedizolid. Eighty-one patients, treated with tedizolid 200 mg once daily for a median (interquartile range [IQR]) duration of 28 (14 to 59) days, were included; 36 (44.4%) had previously received linezolid. The most common reasons for selecting tedizolid were to avoid linezolid potential toxicities or interactions (53.1%) or due to previous linezolid-related toxicities (27.2%). The most common indications were off-label, including prosthetic joint infections, osteomyelitis, and respiratory infections (77.8%). Overall, 9/81 patients (11.1%) experienced a probably associated AE. Two patients (2.5%) developed gastrointestinal disorders, 1 (1.2%) developed anemia, and 6 developed thrombocytopenia (7.4%) after a median (IQR) duration of treatment of 26.5 (17 to 58.5) days. Four (5%) patients discontinued tedizolid due to AEs. Among 23 patients with chronic renal failure (CRF), the rate of myelotoxicity was 17.4%, and only 8.7% had to stop tedizolid; 20 out of 22 with previous linezolid-associated toxicity had no AE. Long-term tedizolid treatments had good tolerance with rates of gastrointestinal AE and hematological toxicity lower than those reported with linezolid, particularly in patients with CRF and in those with a history of linezolid-associated toxicity.
YR 2020
FD 2020-06-23
LK http://hdl.handle.net/10668/15398
UL http://hdl.handle.net/10668/15398
LA en
DS RISalud
RD Apr 18, 2025